ClinicalTrials.gg
RecruitingNCT06879652Updated Mar 5, 2026

The Effect of Dairy Intake on Body Weight and Composition and Metabolic Health in Adolescents and Seniors

An interventional study of Counselling to follow Canada's Food Guide and 3 daily servings of Dairy (long-term study) and Dairy (short-term study) in Dairy Consumption, Metabolic Health and Obesity Prevention, sponsored by University of Toronto. Recruiting at 2 sites in Canada. Open to participants aged 14 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by University of Toronto · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
14 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 53 studies in Obesity by University of Toronto — 4 open to participants now, 7 under way, none of them phase 3. Obesity · University of Toronto.

Planned enrollment
Largest of 38
240 · median 30
Started
2026
the only one that year
No phase
36 of 53
3 open now
Registered
53rd of 53
by date

Among the 53 studies in Obesity by University of Toronto, this one has the largest planned enrollment of the 38 interventional ones that give a count, is the only one that started in 2026, is one of 36 with no phase, and was the 53rd registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

4 of the 53 studies in Obesity by University of Toronto are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 14 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Obesity by University of Toronto, or all of them as a file.
02

Study summary

The goal of this study is to examine how regular dairy intake affects body weight, body composition, and metabolic health in overweight and obese adolescents (ages 15-18) and older adults (ages 60-80) over six months. We are inviting eligible individuals to participate in this study at the Nutrition Intervention Center, Department of Nutritional Sciences, University of Toronto. Participants will be randomly divided into two groups. The intervention (dairy) group will consume three servings of dairy per day (milk, yogurt, and cheese) before breakfast, lunch, and dinner. The control (low-dairy) group will continue their usual diet, keeping dairy intake to less than one serving per day.

Participants will have biweekly sessions with a registered dietitian to be guided to follow Canada's Food Guide, monitor their dietary intake and ensure compliance with their assigned group. In addition, they will visit the Nutrition Intervention Center at weeks 0, 12, and 24 for anthropometric and body composition assessments (weight, height, waist circumference, blood pressure, lean mass, and fat mass), resting metabolic rate, (gait speed, grip strength, and chair stand test just for older adults) and blood markers (fasting blood glucose, insulin, C-peptide, HbA1c, lipid profiles, and inflammatory markers). Each visit will take approximately 4 hours.

Before each visit, the participants will be asked to fast overnight for 12 hours, maintain their usual diet and sleep patterns, and avoid exercise and alcohol the day before. The participants will be compensated for their time and travel expenses.

Our secondary objective is to compare the effects of dairy and plant-based alternative products on blood sugar and appetite regulation in adolescents and older adults. Participants will be asked to come to the Nutrition Intervention Center on 3 separate occasions: once for an in-person screening lasting approximately 30 min and 2 times for study visits lasting approximately 2.5 hrs each. The entire study will take at least 2 weeks to complete. You will be asked to fast for 12 hrs (overnight) before each study visit. You will also be instructed to maintain the same dietary and sleep patterns and refrain from exercise and alcohol consumption on the days before the study visits. During these study visits, you will be asked to consume either a dairy or a plant-based alternative product as well as a pizza meal. You will periodically fill out questionnaires rating your feelings and perceptions, and provide blood samples through finger pricks and intravenously through your forearm to measure blood sugar, insulin, hormones, and amino acids. You will be compensated for your time and travel expenses.

03

Conditions studied

  • Dairy Consumption
  • Metabolic Health
  • Obesity Prevention

Keywords

  • Dairy intake
  • Obesity
  • Type2 Diabetes
  • HbA1c
  • BMI z-score
  • Insulin resistance
  • Adolescents
  • Seniors
04

Who can participate

Ages eligible
14 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria (long-term Study):

  • Age 15-18 years old (adolescents) or 60-80 years old (seniors)
  • z-score >+1SD, \<+2SD (adolescents) or BMI 25-34.9 kg/m2 (seniors)
  • Waist circumference > 80 cm for women and > 94 cm for men (seniors)
  • FBG 5.6-6.9 mmol/L (prediabetes)
  • Willing to follow Canada's Food Guide
  • Willing to maintain current dietary supplement use throughout the study.
  • Willing to abstain from alcohol consumption for 24 hours before all test visits.
  • Willing to avoid vigorous physical activity for 24 hours before all test visits.
  • Understands the study procedures and is willing to provide by the parent/guardian and assent by participant to participate in the study and authorization to release relevant protected health information to the study investigator.

Exclusion Criteria:

  • Fasting BG ≥ 7 mmol/L
  • Blood pressure systolic ≥ 130mmHg or diastolic ≥ 80mmHg (adolescents) or systolic ≥ 140 mmHg or diastolic pressure ≥ 90 mmHg
  • Smoking (tobacco and/or cannabis product use in the last 6 months)
  • Thyroid problems
  • History of CVDs, diabetes, liver or kidney disease, inflammatory bowel disease, celiac disease, short bowel syndrome, any malabsorption syndrome, pancreatitis, gallbladder, or biliary disease.
  • Presence of gastrointestinal disorder or surgeries within the past year.
  • Use of the prescription or non-prescription drugs, herbal or nutritional supplements known to affect the outcome of the study as per the investigator's judgment (including prebiotics and probiotics).
  • Known to be pregnant, lactating, or not for at least a year and/or is taking hormonal treatments
  • Unwillingness or inability to comply with the experimental procedures
  • Known intolerance, sensitivity, or allergy to dairy, gluten, or any other study treatments.
  • Consumption of protein powders/supplements
  • Extreme dietary habits (e.g., Atkins diet, very high-protein diets, etc.)
  • Weight gain or loss of > 5% in the previous three months.
  • Excessive alcohol intake (more than 2 drinks per day or 9 per week)
  • Restrained eating, identified by a score of ≥11 on the Eating Habits Questionnaire

Inclusion Criteria (short-term study):

  • Age 14-18 years old (adolescents) or 60-75 years old (older adults)
  • BMI z-score >+1SD, \<+2SD (adolescents) or BMI 25-30 kg/m2 (older adults)
  • Willing to maintain habitual diet, physical activity pattern, and body weight throughout the study.
  • Willing to maintain current dietary supplement use throughout the study. On study visit days, subject agrees not to take any supplements until dismissal from the Nutrition Intervention Center.
  • Willing to abstain from alcohol consumption for 24hrs prior to all study visits.
  • Willing to avoid vigorous physical activity for 24hrs prior to all study visits.
  • Willing to refrain from cannabis use throughout the entire duration of the study.
  • Willing to refrain from protein supplement use (e.g. protein powder) throughout the entire duration of the study.
  • Understands the study procedures, provides informed consent to participate in the study, and authorizes release of relevant protected health information to the study investigator.

Exclusion Criteria (short-term study):

  • Smoking
  • Thyroid problems
  • Lactose intolerance and/or allergies, intolerances, or sensitivities to study treatments
  • Previous history of cardiovascular disease, diabetes, liver or kidney disease, inflammatory bowel disease, celiac disease, short bowel syndrome, malabsorptive syndrome, pancreatitis, gallbladder or biliary disease
  • Presence of gastrointestinal disorder or surgeries within the past year.
  • Inability to comply with the experimental procedures and follow our safety guidelines
  • Regular breakfast skipping (>3 days a week)
  • On a special diet (e.g. ketogenic, Atkins, high protein) or restrained eaters as identified by a score of >20 on the Eating Attitudes Questionnaire
  • Difficulties with eating or swallowing
  • Fasting blood glucose >5.6mmol/L measured at screening
  • Uncontrolled hypertension (systolic blood pressure >120mmHg, diastolic blood pressure >80mmHg) as defined by the average blood pressure measured at screening
  • Weight gain or loss of >10lbs in previous three months
  • Consuming prescription or non-prescription drug, herbal or nutritional supplements known to affect outcome of the study as per investigator's judgement
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    High Dairy - Adolescents (long-term study)

    Participants in the intervention group will follow Canada's Food Guide and consume 3 servings of dairy per day.

    Other: Counselling to follow Canada's Food Guide and 3 daily servings of Dairy (long-term study)

  • Active comparator
    Low Dairy- Adolescents (long-term study)

    Participants in the control group will adhere to Canada's Food Guide and keep their dairy intake to less than one serving per day.

    Other: Counselling to follow Canada's Food Guide (long-term study)

  • Experimental
    High Dairy - Seniors (long-term study)

    Participants in the intervention group will follow Canada's Food Guide and consume 3 servings of dairy per day.

    Other: Counselling to follow Canada's Food Guide and 3 daily servings of Dairy (long-term study)

  • Active comparator
    Low Dairy- Seniors (long-term study)

    Participants in the control group will adhere to Canada's Food Guide and keep their dairy intake to less than one serving per day.

    Other: Counselling to follow Canada's Food Guide (long-term study)

  • Experimental
    Dairy arm - Adolescents (short-term study)

    Participants will consume 2 servings of dairy milk or yogurt.

    Other: Dairy (short-term study)

  • Experimental
    Plant-based alternative - Adolescents (short-term study)

    Participants will consume 2 servings of a commercially available soy milk or plant-based yogurt.

    Other: Plant-based alternative (short-term study)

  • Experimental
    Dairy arm - Seniors (short-term study)

    Participants will consume 2 servings of dairy milk or yogurt.

    Other: Dairy (short-term study)

  • Experimental
    Plant-based alternative - Seniors (short-term study)

    Participants will consume 2 servings of a commercially available soy milk or plant-based yogurt.

    Other: Plant-based alternative (short-term study)

Interventions

  • OtherCounselling to follow Canada's Food Guide and 3 daily servings of Dairy (long-term study)

    Participants aged 15-18 and 60-80 years who are randomly assigned to the intervention group will follow Canada's Food Guide and consume 3 servings of dairy (milk, yogurt, cheese) per day for 24 weeks.

  • OtherDairy (short-term study)

    The dairy products that participants will be required to consume include: 1) Trial 1: 2% cow's milk; 2) Trial 2: dairy yogurt.

  • OtherCounselling to follow Canada's Food Guide (long-term study)

    Participants will be instructed to follow Canada's Food Guide.

  • OtherPlant-based alternative (short-term study)

    The plant-based products that participants will be required to consume include: 1) Trial 1: soy beverage; 2) Trial 2: plant-based yogurt;

06

What researchers measure

Primary outcomes

  1. Body Fat Mass (kg)

    Body Fat Mass (BFM) is the primary outcome in the long-term study of the senior group. It will be measured using bioelectrical impedance analysis (BIA).

    Time frame: BFM will be measured at weeks 0, 6, 12, 18, and the end of the study (week 24).

  2. Lean body mass (Kg)

    Lean body mass (LBM) is the primary outcome in the long-term study of the senior group. It will be measured using bioelectrical impedance analysis (BIA).

    Time frame: LBM will be measured at weeks 0, 6, 12, 18, and the end of the study (week 24).

  3. Body Mass Index (BMI) z-score

    BMI z-score, the primary outcome in the long-term study of the adolescent group, is an age- and sex-adjusted measure of BMI in adolescents. It will be calculated using height and weight measurements and interpreted using WHO growth charts and percentiles.

    Time frame: BMI z-score will be measured at the beginning (week 0), midpoint (week 12), and end of the study (week 24).

  4. Blood Glucose (mmol/L) (short-term study)

    Blood glucose, the primary outcome in the short-term studies of adolescents and seniors, will be measured via finger-prick using a glucometer at 0, 5, 20, 35, 50, 65, 95, 125, and 145 minutes after treatment consumption.

    Time frame: Over 145 minutes after treatment consumption at each session, for a total of 2 weekly sessions.

Secondary outcomes

  1. Fasting blood glucose (FBG) (mmol/L)

    FBS will be measured to assess glycemic control in long-term studies of adolescents and seniors. It will be measured using a finger-prick blood sample and a glucometer after a 12-hour overnight fast.

    Time frame: FBS will be measured at the beginning (week 0), midpoint (week 12), and end of the study (week 24).

  2. HbA1c (%)

    HbA1c measures average blood glucose levels over the past 2-3 months. It will be measured in plasma obtained through intravenous blood collection after a 12-hour overnight fast in long-term studies of adolescents and seniors.

    Time frame: HbA1c will be measured at the beginning (week 0), midpoint (week 12), and end of the study (week 24).

  3. Insulin (µU/mL)

    Insulin levels will be measured in plasma obtained through intravenous blood collection after a 12-hour overnight fast in long-term studies of adolescents and seniors.

    Time frame: Insulin will be measured at the beginning (week 0), midpoint (week 12), and end of the study (week 24).

  4. C-Peptide (pmol/L)

    C-peptide levels will be measured in plasma obtained through intravenous blood collection after a 12-hour overnight fast in long-term studies of adolescents and seniors.

    Time frame: C-Peptide will be measured at the beginning (week 0), midpoint (week 12), and end of the study (week 24).

  5. Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)

    HOMA-IR will be calculated as (Fasting Insulin \[µU/mL\] × Fasting Glucose \[mmol/L\]) / 22.5 to assess insulin resistance in long-term studies of adolescents and seniors.

    Time frame: HOMA-IR will be measured at the beginning (week 0), midpoint (week 12), and end of the study (week 24).

  6. Total cholesterol (TC) (mmol/L)

    TC levels will be measured in plasma obtained through intravenous blood collection after a 12-hour overnight fast in long-term studies of adolescents and seniors.

    Time frame: TC will be measured at the beginning (week 0), midpoint (week 12), and end of the study (week 24).

  7. Low-density lipoprotein cholesterol (LDL-C) (mmol/L)

    LDL-C levels will be measured in plasma obtained through intravenous blood collection after a 12-hour overnight fast in long-term studies of adolescents and seniors.

    Time frame: LDL-C will be measured at the beginning (week 0), midpoint (week 12), and end of the study (week 24).

  8. High-density lipoprotein cholesterol (HDL-C) (mmol/L)

    HDL-C levels will be measured in plasma obtained through intravenous blood collection after a 12-hour overnight fast in long-term studies of adolescents and seniors.

    Time frame: HDL-C will be measured at the beginning (week 0), midpoint (week 12), and end of the study (week 24).

  9. Triglycerides (mmol/L)

    Triglyceride levels will be measured in plasma obtained through intravenous blood collection after a 12-hour overnight fast in long-term studies of adolescents and seniors.

    Time frame: Triglycerides will be measured at the beginning (week 0), midpoint (week 12), and end of the study (week 24).

  10. C-Reactive protein (CRP) (mg/L)

    CRP, a marker for assessing systemic inflammation, will be measured in plasma obtained through intravenous blood collection after a 12-hour overnight fast in long-term studies of adolescents and seniors.

    Time frame: CRP will be measured at the beginning (week 0), midpoint (week 12), and end of the study (week 24).

  11. Interleukin-6 (IL-6) (pg/mL)

    Interleukin-6 levels will be measured in plasma obtained through intravenous blood collection after a 12-hour overnight fast in long-term studies of adolescents and seniors.

    Time frame: Interleukin-6 will be measured at the beginning (week 0), midpoint (week 12), and end of the study (week 24).

  12. Leptin (ng/mL)

    Leptin levels will be measured in plasma obtained through intravenous blood collection after a 12-hour overnight fast in long-term studies of adolescents and seniors.

    Time frame: Leptin will be measured at the beginning (week 0), midpoint (week 12), and end of the study (week 24).

  13. Adiponectin (µg/mL)

    Adiponectin levels will be measured in plasma obtained through intravenous blood collection after a 12-hour overnight fast in long-term studies of adolescents and seniors.

    Time frame: Adiponectin will be measured at the beginning (week 0), midpoint (week 12), and end of the study (week 24).

  14. Resting Metabolic Rate (RMR) (kcal/day)

    RMR will be measured using indirect calorimetry after an overnight fast and at least 30 minutes of rest in a thermoneutral environment.

    Time frame: RMR will be measured at the beginning (week 0) and end of the study (week 24).

  15. Blood pressure (BP) (mmHg)

    Blood pressure will be measured in long-term studies of adolescents and seniors, using an automated sphygmomanometer after the participant has been seated and at rest for 10 minutes.

    Time frame: BP will be measured at the beginning (week 0), midpoint (week 12), and end of the study (week 24).

  16. Waist circumference (WC) (cm)

    WC will be measured in long-term studies of adolescents and seniors to assess abdominal adiposity using a standardized measuring tape at the midpoint between the lowest rib and the iliac crest while the participant is in a standing position.

    Time frame: WC will be measured at the beginning (week 0), midpoint (week 12), and end of the study (week 24).

  17. Body Mass Index (BMI) (kg/m²)

    BMI will be calculated to assess overall adiposity in seniors using weight and height measurements, applying the formula: BMI = weight (kg) / height (m²).

    Time frame: BMI will be measured at the beginning (week 0), midpoint (week 12), and end of the study (week 24).

  18. Gait speed (m/s)

    Gait speed will be assessed in a long-term study of seniors using a standardized 4-meter walk test as an indicator of physical function.

    Time frame: Gait speed will be measured at weeks 0, 6, 12, 18, and 24.

  19. Grip strength (kg)

    Grip strength will be assessed in the long-term study of seniors, using a hand dynamometer as a measure of muscle strength.

    Time frame: Grip strength will be measured at weeks 0, 6, 12, 18, and 24.

  20. Chair stand test

    The 30-second chair stand test will be used to assess lower-body strength in the long-term study of seniors. The number of completed stands within 30 seconds will be recorded.

    Time frame: The chair stand test will be performed at weeks 0, 6, 12, 18, and 24.

  21. Urinary Urea Nitrogen (UUN)

    Urinary urea nitrogen will be measured from a complete 24-hour urine collection in a subset of participants to estimate dietary protein intake and nitrogen balance in this long-term study of seniors.

    Time frame: Urinary urea nitrogen will be measured at baseline (week 0) and at week 24.

  22. Insulin (µU/mL) (short-term study)

    Insulin will be measured in the plasma through intravenous blood collection at 0, 35, 65, 125, and 145 minutes after treatment consumption.

    Time frame: Over 145 minutes after treatment consumption at each session, for a total of 2 weekly sessions.

  23. C-peptide (nmol/L) (short-term study)

    C-peptide will be measured in the plasma through intravenous blood collection at 0, 35, 65, 125, and 145 minutes after treatment consumption.

    Time frame: Over 145 minutes after treatment consumption at each session, for a total of 2 weekly sessions.

  24. Glucagon-like Peptide-1 (GLP-1) (short-term study)

    GLP-1 will be measured in the plasma through intravenous blood collection at 0, 35, 65, 125, and 145 minutes after treatment consumption.

    Time frame: Over 145 minutes after treatment consumption at each session, for a total of 2 weekly sessions.

  25. Amino acids (µmol/L) (short-term study)

    Amino acid concentrations will be measured in the plasma through intravenous blood collection at 0, 35, 65, 125, and 145 minutes after treatment consumption.

    Time frame: Over 145 minutes after treatment consumption at each session, for a total of 2 weekly sessions.

  26. Subjective Appetite (short-term study)

    Subjective appetite will be assessed through Adaptive Visual Analogue Scales (AVAS) questionnaires completed at 0, 5, 20, 35, 50, 65, 95, 125 and 145 minutes after treatment consumption and through an ad libitum pizza meal provided at 125 minutes post-treatment consumption, where participants will be instructed to eat until they are comfortably full over 20 minutes.

    Time frame: Over 145 minutes after treatment consumption at each session, for a total of 2 weekly sessions.

  27. Food intake (Kcal) (short-term study)

    Ad libitum food intake (kcal) will be assessed during a standardized pizza meal provided 2 hours after treatment consumption, consumed over 20 minutes.

    Time frame: Assessed from 125 to 145 minutes following treatment consumption.

Other outcomes

  1. Dietary intake

    Dietary intake and adherence to Canada's Food Guide will be assessed using a 3-day food record, the modified Canadian Food Intake Screener (mCFIS), the Canadian Eating Practices Screener (CEPS), and a knowledge, attitude, and practice questionnaire (KAPQ).

    Time frame: Three-day food records will be collected every six weeks; the mCFIS and CEPS will be administered monthly; and the KAPQ will be administered at weeks 0, 12, and 24.

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — IPD will not be shared, as all data will be de-identified and pooled during the analysis. Only researchers directly involved in the study will have access to the data.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Jun 2027, 12 months later.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 12 months is below that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2025
First posted
Mar 17, 2025
StartEst.
Jun 1, 2026
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2028
Last update
Mar 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06879652
Responsible party
G. Harvey Anderson (Professor, University of Toronto) — Principal investigator
First posted
Mar 17, 2025
Start date
Jun 1, 2026 (estimated)
Primary completion
Jun 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Mar 5, 2026

Study contacts

Shekoufeh Salamat, Ph.D.
Contact
s.salamat@utoronto.ca
647-657-5242
Corrina Zhou, MSc
Contact
corrina.zhou@mail.utoronto.ca
416-946-3802
G Harvey Anderson, Ph.D.
principal investigator · University of Toronto

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion